F Star Therapeutics Inc Revenue Growth Rates (FSTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
F star Therapeutics Inc   (NASDAQ: FSTX)
 

FSTX's Revenue Growth by Quarter and Year

F Star Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

FSTX Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 1.13
2nd Quarter June 0.00
1st Quarter March 2.55
FY 3.68





FSTX Revenue third quarter 2022 Y/Y Growth Comment
F star Therapeutics Inc reported Revenue rise of 50% year on year in the third quarter 2022, to $ 1.13 millions, this is lower than F Star Therapeutics Inc 's recent average Revenue surge of 930%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 80 other companies have achieved higher Revenue growth. While F Star Therapeutics Inc ' s Revenue jump of 50% ranks overall at the positon no. 746 in the third quarter 2022.


FSTX Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 10837.5 % - -
3rd Quarter September 50 % -91.85 % - -
2nd Quarter June - - - -
1st Quarter March -12.67 % 114.71 % - -
FY   - 88.01 % - -

Financial Statements
F Star Therapeutics Inc 's third quarter 2022 Revenue $ 1.13 millions FSTX's Income Statement
F Star Therapeutics Inc 's third quarter 2021 Revenue $ 0.75 millions Quarterly FSTX's Income Statement


FSTX Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 2233.33 % -98.26 % -
3rd Quarter September - - 1603.7 % -
2nd Quarter June - - -60.29 % -
1st Quarter March -85.43 % 1725 % - -
FY (Year on Year)   - 88.01 % - -


Back to FSTX Growth rate Comparisons >> Back to FSTX Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #81
Healthcare Sector #171
Overall #746

Revenue Y/Y Growth Statistics
High Average Low
10635.58 % 930 % -100 %
(Dec 31 2021)   (Jun 30 2017)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #81
Healthcare Sector #171
Overall #746
Revenue Y/Y Growth Statistics
High Average Low
10635.58 % 930 % -100 %
(Dec 31 2021)   (Jun 30 2017)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

F Star Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FSTX's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FSTX's III. Quarter Q/Q Revenue Comment


F Star Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Sep 30 2022 period, F Star Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

F star Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2022 period, F Star Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

F star Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FSTX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Biocryst Pharmaceuticals Inc 84.97%$ 84.971 millions
Intellia Therapeutics Inc 84.15%$ 84.148 millions
Seer Inc 83.53%$ 83.527 millions
Stablecoin Development Corporation83.42%$ 83.424 millions
Halozyme Therapeutics Inc 80.42%$ 80.416 millions
Solana Company79.82%$ 79.817 millions
Immunitybio inc 78.79%$ 78.788 millions
Sintx Technologies Inc 78.24%$ 78.243 millions
Molecular Templates Inc 78.23%$ 78.226 millions
Arbutus Biopharma Corp78.20%$ 78.204 millions
Icu Medical Inc77.90%$ 77.902 millions
Inspire Medical Systems inc 77.01%$ 77.009 millions
Tff Pharmaceuticals Inc75.20%$ 75.200 millions
Pulmatrix Inc 75.12%$ 75.117 millions
Delcath Systems Inc 73.56%$ 73.563 millions
1life Healthcare Inc 72.71%$ 72.711 millions
Akumin Inc 72.50%$ 72.500 millions
Valion Bio Inc 72.20%$ 72.202 millions
Cvrx inc 72.19%$ 72.194 millions
Imagenebio Inc 70.90%$ 70.902 millions
Biodesix Inc 70.07%$ 70.066 millions
Lexicon Pharmaceuticals Inc 69.57%$ 69.565 millions
Nexgel Inc 69.55%$ 69.552 millions
Greenlight Biosciences Holdings Pbc68.65%$ 68.647 millions
Dariohealth Corp 68.37%$ 68.366 millions
Progyny Inc 67.95%$ 67.946 millions
Aclarion Inc 67.17%$ 67.174 millions
Immunogen inc 66.94%$ 66.938 millions
Infinity Pharmaceuticals Inc 66.36%$ 66.355 millions
Checkpoint Therapeutics inc 65.52%$ 65.517 millions


About F Star Therapeutics Inc Revenue Growth Rates (FSTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: F star Therapeutics Inc (CIK 1566373).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-024526
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: F star Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.